biotech investment showcase€¦ · conference and commercial speakers includes: • olga krylova,...
TRANSCRIPT
For Booking details and registration fees, please email [email protected] or visit
www.biotechinvestment-showcase.com
BIOTECH INVESTMENT SHOWCASE
22-23 May 2018, London, UK
Event Sponsors:
Industry speakers, investors and commercial speakers:
2018 Biotech Investor Showcase and Start-up Slam, 22nd - 23rd May 2018, London
The 2018 Biotech Investment showcase is the UK and Europe's most focussed and leading-edge funding,
investment and partnering forum in the biotech sector, hosting over 300 attendees. Leading VC funds,
pharma investors, hedge funds, emerging successful biotech spinoffs, early stage biotech discovery and
clinical companies as well as KOLs in the sector will be attending this one of a kind showcase event on
the 22nd & 23rd May 2018 in London. The event will help to identify the key technological and scientific
investment areas in the sector and will also offer a unique networking, partnering and business
development opportunity for those involved.
What does the showcase consist of?
Biotech Investment Conference Speakers, and Start up Slam Judging Faculty
Biotech Investment conference
programme and showcase
• An educational programme
with over 60 presentations,
postulating topics on scientific,
technological and investment
growth in the industry
• Over 50 biotech spinoffs,
early stage discovery and clinical
company product presentations
during the 2 days
• Two dedicated Startup Slam
Sessions and supported by a 20-
strong judging expert faculty
Networking opportunities &
scheduled business partnering
meetings
• Over 35 Scheduled business
partnering meetings
• Exhibition area with coffee
and lunch breaks
• Poster presentation
spotlights
• Pre-dinner reception and
networking drinks
Corporate Gala Dinner and
Awards
• Gala dinner and awards
ceremony featuring the best
scientist award categories
• Live polling throughout the
dinner on industry hot topics
• Supporting Cancer
Research UK through each event
evaluation form received
Start Up Slam
At the showcase event, there are two dedicated sessions on the agenda for start-up entrepreneurs or
scientists like yourselves to present your new product and research in front of leading pharma and
biotech venture companies, VCs and Technology Transfer offices.
If you are developing an innovative product or technology in the following areas, please email
• NGS/Single Cell/Genomics Technologies/dPCR/Microfluidics
• Microbiome Discovery and Development
• Artificial Intelligence and Digital Health
• Immuno-Oncology and Immuno-Therapy
• Biomarkers/Precision Medicine/ Liquid Biopsy
Lori L. Badura,
EMD Serono
Melanie Goward
Maven Capital Maciek Drozdz,
Johnson & Johnson Bent Jakobsen,
Immunocore Olga Krylova
Pfizer Mouad Lamrani
Menicon Co., Ltd
Anne Goubier
Tusk Therapeutics Timothy Herpin
Astra Zeneca Torsten Hoffmann
Silence
Therapeutics
Olga Kubassova,
IAG
Tony Hickson
Imperial Innovations
Ltd
Avi Spier
Novartis
John Haurum
F-star
Tim Kievits
VitrOmics Rakesh Dixit
Medimmune
Philip Arlen
Precision Biologics
Peter Dudek
Wellington Partners
Kristin Wannerberger
Ferring
Conference and commercial speakers Includes:
• Olga Krylova, Senior Director, Global Scouting, UK, External Science & Innovation, Pfizer
• Rakesh Dixit, Vice President, Research & Development, Global Head, Biologics Safety Assessment, Medimmune
• Morten Lindow, Director, Innovation and Project Excellence, Roche
• Ro Wickramasinghe, Director of Oncology Evaluation, AstraZeneca
• Bent Jakobsen, Chief Scientific Officer, Immunocore
• Kristin Wannerberger, Director R&D Alliance Management, Ferring International Center S.A
• Bernhard Paetzold, Founder, S-Biomedic
• Mouad Lamrani, Director of R&D Innovation Center, Menicon Co., Ltd
• Torsten Hoffmann, Chief Operating Officer, Silence Therapeutics
• Tommi Lehtonen, CEO, Blueprint Genetics
• Davide Danovi, Director, Centre for Stem Cells & Regenerative Medicine, King's College London
• Patrice Garnier, CEO, AMABIOTICS
• Patrick Gillevet, Professor, Director, George Mason University, Director of the Microbiome Analysis Center
• Andreas Kungl, CEO, Antagonis
• Assaf Oron, Chief Business Officer, BiomX
• David Llewellyn, CEO, DJS Antibodies
• Ron Alfa, VP of Discovery and Product, Recursion Pharmaceuticals
• Mihriban Tuna, Vice President, Drug Discovery, F-star Biotechnology Ltd.
• John Haurum, CEO, F-star GmbH & F-star Biotechnology Ltd.
• Philip M. Arlen, President & Chief Executive Officer, Precision Biologics, Inc.
• Fred Jacobs, CEO, TYG Oncology
• Imke Mulder, Research Director, 4D Pharma Research Ltd
• Xavier Duportet, CEO, Eligo Bioscience
• Leonardo Rodrigues, Associate Director - Advanced Analytics, BERG
• Rajiv Gogna, Co-Founder & CEO, Resurgo Genetics
• Anne Goubier, VP Immunology, Tusk Therapeutics
• Sowmiya Moorthie, Senior Policy Analyst (Epidemiology), PHG Foundation
• Mohammed Kamran, CEO & Medical Director, Future Genetics
• Christopher Primiano, Senior Vice President, Operations, Business Development, Karyopharm Therapeutics
• Marko Lehes, Founding CEO, SelfDiagnostics
• Edward Green, Chief Executive, CHAIN Biotechnology Ltd
• Tina Flatau, Managing Director, MedAnnex
• Mike Karim, CEO, Oxford Endovascular Limited
• Keith Errey, CEO, Isansys
• Will Dracup, CEO, Biosignatures
• Romain Micol, President, CEO, Co-Founder, Combined Therapeutics
• Stephen B. Parker, Chairman, Sareum Holdings plc
• Sandy Primrose, Non-Executive Chairman, Urosens
• Janusz Dutkowski, Founder and CEO, Data4Cure Inc
• Heinrich Roder, CTO, Biodesix
• Caroline Barelle, CEO, Elasmogen
• Aviv Boim, CEO, Tikcro Technologies Ltd
• Olga Kubassova, Chief Executive Officer, IAG
• Tim Kievits, Director Healthcare Innovation, VitrOmics Healthcare Holding B.V.
• Hugh Ilyine, CEO, DestiNA Genomics
• Stuart Hassard, Chief Scientific Officer, deltaDOT Ltd
Investors, Pharma Ventures and Alliance speakers:
• Peter Dudek, Principal, Wellington Partners Life Science Venture Capital
• Stephan Christgau, Investment Director, Novo Seeds
• Christina Takke, Managing Partner, V-Bio Ventures
• Daniel Oliver, CEO, Capital Cell
• Oskar Slotboom, Partner, BGV
• Gerard Honing, Translational Research Manager, Crohn's & Colitis Foundation
• Patrik Frei, Founder and CEO, Venture Valuation AG
• Felice van Weegen, Investment Associate, LSP Life Sciences
• Michael Anstey, Investment Director, Cambridge Innovation Capital
• Hakim Yadi, CEO, Northern Health Science Alliance
• Savvas Neophytou, Partner, Head of Life Sciences, Deepbridge Capital LLP
• Piyush Unalkat, Head of Unit – Equity Investments, European Investment Fund
• Melanie Goward, Investment Director, Maven Capital
• Vijay Barathan, Life Science Partner, Catapult Ventures
• Tony Hickson, Managing Director, Imperial Innovations Ltd
• Lori L. Badura, Director, Evaluation and Licensing, Global Business Development and Alliance Management, EMD Serono
• Maciek Drozdz, Principal of Venture Investments, Johnson and Johnson Development Corporation
• Avi Spier, Director, NIBR BD&L, Search and Evaluation, GNF Systems and Microbiome, Novartis (Reserved)
• Timothy Herpin, Vice President, Head of Transactions Business Development, AstraZeneca
• Keith Woodhouse, Partner, Fieldfisher
• Simon Haworth, CEO, Dynastybio
• Irina Haivas, Principal, GHO Capital Partners
DAY 1 – Stream 2
Microbiome Discovery and Development
➢ Machine learning and Data Analysis
➢ AI application in Pharma R&D
➢ Genomics, Big Data Analysis and Deep Learning
➢ AI and Precision medicine
➢ AI, Robotics and Machine Learning: leading data science and
machine learning
➢ Integrated Healthcare and Digital health
➢ Medical devices development for Cardiovascular, and
Neurovascular Diseases
➢ Medical Diagnostics
➢ Digital healthcare solutions
DAY 1 – Stream 1
NGS/Genomics Technologies/dPCR/Microfluidics
DAY 1 – Stream 3
Pharma Technologies, Artificial Intelligence, Medical Devices
and Digital Health
➢ Innovations of NGS in pharma: biomarker development,
precision medicine and clinical diagnostics
➢ NGS, genomics and clinical diagnostics in healthcare
➢ NGS Data Analysis & NGS Application Strategies
➢ Single Cell ‘Omics Analysis: Current and Emerging Tools
➢ Single Cell Analysis - Translation to Diagnostic and Therapeutic
Applications
➢ Single Cell Data Analysis & Advances in Microfluidic
Technologies
➢ Microbiome Discovery & Technologies
➢ Translational Science of the Microbiome
➢ Novel Genomic Technologies
➢ Next Generation Sequencing technologies
➢ Data Management in Microbiome Discovery
➢ Bacterial Pathogens and the Microbiome
➢ Small Molecule Microbiome Discovery
➢ Discovery and development of Microbiome Therapeutics in
Metabolic Disorders, Inflammatory Conditions, Women’s
Health, Dysbiosis
➢ Immune monitoring
➢ Clinical trial design and management
➢ Translational biomarkers
➢ Microbiome and Immuno-oncology
➢ Cancer Immunoassays for biomarker development
➢ CAR T Cell Therapy
➢ Immuno-oncology Therapeutic Development
DAY 2 – Stream 1
Immuno-Oncology and Immuno- Therapy – Discovery and
Development
➢ Precision Medicine, Companion Diagnostics, Molecular
Diagnostics Development
➢ Innovations in Biomarkers Research, Assay
Development, Imaging, Data Integration Methods,
Bioinformatics, Trial Design
➢ Molecular Diagnostics Development
➢ Genomic approaches in drug development
➢ Advances made in NGS techniques in liquid biopsy
➢ RNAseq NGS in biomarker benchmarking
Day 2 - Stream 2
Proteins, Antibodies, Regenerative Medicine Discovery and Development
Gain insights and learn from over 60 expert speakers from pharmaceutical, biotech, academic, medical devices and
investment companies
Assessing the potential of artificial intelligence in drug discovery and development, machine learning and patient monitoring
Learn about the latest medical devices development in Neurovascular, Cardiovascular and Cancer related diseases
Benefit from updates in Protein, Antibodies, Peptides and Cell based biotherapeutic development
Maximising your knowledge on the key discovery and development strategies in Immunotherapy, Immuno-oncology, Biologics
and Microbiome
Identifying the key technologies in accelerating the genomics revolution
Exploiting Biomarker technologies in clinical development, precision medicine and diagnostics development
Evaluating and overcoming the challenges of finding and funding innovation for Biotech spinoffs
Gaining insights from the Partnering and Licensing Innovations in the Pharma & Biotech industry
Attendee Benefits
Do not miss out on presenting on the speaker programme, featuring presentations by:
✓ Emerging university spin offs and entrepreneurial companies to access to interested VC funds and investors
✓ Academic researchers and technology transfer offices to present an IP or idea to funding and development partners
✓ Biotech companies to partner their products, form alliances and develop global financing contacts
For speaking opportunities, please email [email protected]
➢ Advancing to the clinic: antibody drug conjugates
➢ Innovative design and engineering approaches
➢ Fusion protein therapeutics
➢ New targets & new indications for protein biotherapeutics
➢ Accelerating antibody discovery & optimisation:
➢ Stem Cell Research
➢ Cell and Gene Therapy
DAY 2 – Stream 3
Biomarkers/Precision Medicine/ Liquid Biopsy in Drug and
Clinical Development/Molecular Diagnostics Development
08.00-08.30
Keynote Address- Addressing R&D Innovation
• Therapeutic areas in focus
• Partnering and open innovation
Sponsored by:
08.30-09.00
Panel Discussion - Artificial Intelligence and Digital Health
• Analysis of the Artificial Intelligence market: Drug Discovery and Development, Machines Learning and Patient
Monitoring
• Digital healthcare and integrated healthcare
• Innovation – clinical validation, market access and scale up in the UK
Panellists: Vijay Barathan, Life Science Partner, Catapult Ventures
Felice Verduyn - van Weegen, Investment Associate, LSP Life Sciences
Leonardo Rodrigues, Associate Director - Advanced Analytics, BERG
Ron Alfa, Vice President, Discovery & Product, Recursion Pharmaceuticals
Hakim Yadi, CEO, Northern Health Science Alliance
09.00-09.30
Panel Discussion - Accelerating Genomics Revolution
• Adoption of NGS
• Moving to single-cell biology
• Clinical Diagnostics
• cell-free DNA
• dPCR
• Microfluidics
Panellists:
Torsten Hoffmann, Chief Operating Officer, Silence Therapeutics
Sowmiya Moorthie, Senior Policy Analyst, PHG Foundation
Tommi Lehtonen, CEO, Blueprint Genetics
EMD Serono
09.30-10.00
Panel Discussion - Innovation in the Pharma & Biotech – Partnership Strategies
• Innovation in practice – how partnerships are formed in Pharma
• The latest drug research and development efforts, success and paths to commercialisation
• Realising the true value of academic-industry collaboration
• Playing to your strengths - early-stage technology collaborations
Panellists:
Olga Krylova, Senior Director, Global Scouting, UK, External Science & Innovation, Pfizer
Stephen B. Parker, Chairman, Sareum Holdings plc
Olga Kubassova, Chief Executive Officer, IAG
10.00-10.30 Morning Refreshment Break
Stream 1: NGS/Genomic
Technologies/dPCR/ Microfluidics
Stream 2: Drug Discovery and
Development – Microbiome,
Immuno-oncology, Oncology
Stream 3: Pharma IT, Artificial
Intelligence, Medical Devices,
and Digital Health
Scheduled Partnering
Meetings x8 and
Exhibition
10.30-10.45 Laura Roca-Alonso, Chief Business
Officer, Silence Therapeutics
Alex Blyth, CEO, LiftBioSciences
AI And Variant Classification In
Rare Disorder Diagnostics
Tommi Lehtonen, CEO, Blueprint
Genetics
DAY 1 Agenda At A Glance
10.45-11.00
Spinoffs and emerging biotech
company presentation
New Generation of Therapeutic
and Intelligent mRNA
Romain Micol, President, CEO,
Co-Founder, Combined
Therapeutics
Decoding 'Junk' DNA: An AI
Approach To Novel
Therapeutics
Rajiv Gogna, Co-Founder & CEO,
Resurgo Genetics
11.00-11.15
Jerome Dubos, Business Developer,
DNA Script
Aviv Boim, CEO, Tikcro
Technologies Ltd
Spinoffs and emerging biotech
presentation
11.15-11.30
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging biotech
presentation
11.30-12.00 Panel Discussion: Microbiome Discovery and Development
• What are the most successful microbiome trends with clear therapeutic potential?
• What are the potential challenges of microbiome drug development?
• Playing to your strengths - early-stage technology collaborations
Moderator:
Panellists:
Maciek Drozdz, Principal of Venture Investments, Johnson and Johnson Development Corporation
Kristin Wannerberger, Director R&D Alliance Management, Ferring International Center S.A
Bernhard Paetzold, Founder, S-Biomedic
Patrick Gillevet, Professor & Director, Department of Biology and MicroBiome Analysis Center, George
Mason University
Xavier Duportet, CEO, Eligo Bioscience
Spinoffs and emerging biotech company presentation
Spinoffs and emerging biotech presentation
12.00-12.30 Machine Learning and Sequence Analysis As Enablers Of RNA Drug Discovery
Morten Lindow, Director, Innovation and Project Excellence, Roche
Stream 1: NGS/Genomic
Technologies/dPCR/ Microfluidics
Stream 2: Drug Discovery and
Development – Microbiome
Stream 3: Pharma
Technologies, Artificial
Intelligence, Medical Devices,
and Digital Health
12.30-13.30 Lunch
13.30 – 14.00
Single Cell Analysis - Translation
To Diagnostic and Therapeutic
Applications
Microbiome Discovery and
Development
Edward Green, Chief Executive,
CHAIN Biotechnology Ltd
AI and Precision medicine
Ron Alfa, Vice President,
Discovery & Product, Recursion
Pharmaceuticals
Scheduled Partnering
Meetings x9 and
Start Up Slam
DAY 1 Agenda at a Glance
14.00 – 14.30 Immunosequencing - Enhancing
Immunotherapy discovery and
Development
M. Allen Northrup CEO, MIODx
(TBC)
From Microbiome
Explorations to Effective
Innovative Therapies in
Parkinson Disease: a case
study
• From biochemical
mechanisms to proof of
concept: how to design a
new microbiome-oriented
strategy for Parkinson
Disease;
• Preclinical and clinical trials:
the same road as
pharmaceutical
development?
Patrice Garnier, CEO,
AMABIOTICS
Machine Learning and Data
Analysis
Leonardo Rodrigues, Associate
Director - Advanced Analytics,
BERG
14.30 – 15.00 Collaborative Phenotyping at
King’s College London: HipSci and
the Stem Cell Hotel • Characterisation of a large panel of
Human Induced Pluripotent Stem
Cells (see www.hipsci.org)
• Integration of High Content imaging
with other datasets such as genomics,
transcriptomics, proteomics
• Opening of a collaborative
phenotyping space to internal and external scientists and technology
providers Davide Danovi, Director, HipSci
Cell Phenotyping, Centre for Stem
Cells & Regenerative Medicine,
King's College London
Microbiome and Drug
Discovery in Ferring • The Human Microbiome
Translational Research
Program
• Bacteriophages
Kristin Wannerberger,
Director R&D Alliance
Management, Ferring
International Center S.A
Medical Devices And Digital
Healthcare Solutions
Marko Lehes, Founding CEO,
SelfDiagnostics
15.00 – 15.30 NGS, Genomics And Clinical
Diagnostics In Healthcare
Customized phage therapies
that target and destroy
harmful bacteria in chronic
diseases such as
inflammatory bowel disease
(IBD) and cancer
• Growing evidence in chronic
diseases such as IBD
and colon cancer of need
for targeted eradication of
harmful bacteria present in
the microbiome
• BiomX discovers and
validates proprietary
harmful bacterial targets
and customizes natural and
engineered phage
compositions against these
targets
• BX002, a novel customized
phage therapy for IBD
expected to enter clinical
trials in 2019
Assaf Oron, Chief Business
Officer, BiomX
Digital Health Case Study
Keith Errey, CEO, Isansys
DAY 1 Agenda at a Glance
15.30 – 16.00 NGS, Genomics And Clinical
Diagnostics In Healthcare
• Exploration of the current British
clinical practice landscape and
genomics
• Gaining buy-in from NHS and
the public: challenges around
consent and data sharing
• The promise of NGS and the
(significant) barriers associated to
that delivery
• Delivering the Promise: The
consequence of differing outcomes
for patients & society
Mohammed Kamran, CEO & Medical
Director, Future Genetics
Microbiome Drug
Development Case Study
Imke Mulder, Research
Director, 4D Pharma Research
Ltd
Artificial Intelligence and
Precision Medicine
Janusz Dutkowski, Founder and
CEO, Data4Cure, Inc
16.00-16.30 Afternoon Refreshments
16.30-17.00
Panel Discussion: Join Our Panellists As They Address The Challenges Of Finding And Funding Innovation For Biotech
Spinoffs
• De-risking biotech projects in the university environment prior to spinout or licence – a good or bad idea?
• The importance of patient capital for early stage biotech investments
• Other models of funding therapeutic development projects (e.g. Licensing funds and project aggregators)
Moderator:
Tony Hickson, Managing Director, Imperial Innovations Ltd
Panellists:
Stephan Christgau, Investment Director, Novo Seeds
Tina Flatau, Managing Director, MedAnnex
Gerard Honing, Translational Research Manager, Crohn's & Colitis Foundation
Michael Anstey, Investment Director, Cambridge Innovation Capital
17.00 – 17.30 Panel Discussion: Other Financing Opportunities for Innovation
• Viewpoints on investment landscape and investor sources
• Ensuring mutually beneficial incentives
• Terms and deal structures
• Collaboration and syndication
For - Angel investment options
For - Private Financing options
For - Venture Capital options
For – Seed Investors
Panellists:
Christina Takke, Managing Partner, V-Bio Ventures
Daniel Oliver, CEO, Capital Cell
Oskar Slotboom, Partner, Biogeneration Ventures
Piyush Unalkat, Head of Unit – Equity Investments, European Investment Fund
Savvas Neophytou, Partner, Head of Life Sciences, Deepbridge Capital LLP
17.30-18.00 Panel Discussion – Medical Devices Development for Cardiovascular, And Neurovascular Diseases
• Trends and innovations of the medical device manufacturing
• Regulatory requirements
• What are investors looking for?
• Communicating with key stakeholders
Panellist: Mike Karim, CEO, Oxford Endovascular Limited
18.00-18.30 Drinks Reception and Sponsored Awards Dinner
END OF DAY ONE
DAY 1 Agenda at a Glance
08.00-08.30
Keynote Address – Biomarker Clinical Market Development, Companion Diagnostics Development And
Targeted Therapy
08.30-09.00 Panel Discussion – Accelerating Antibody Discovery & Optimisation:
• Bispecific antibodies
• Monoclonal antibodies
• Antibody drug conjugates
Panellists:
Mihriban Tuna, Vice President Drug Discovery, F-star Biotechnology Ltd
David Llewellyn, CEO, DJS Antibodies
09.00-09.30
Panel Discussion – Precision Medicine - Biomarkers and Diagnostics in Targeted Patient Therapy
Panellists:
Lori L. Badura, Director, Evaluation and Licensing, Global Business Development and Alliance Management Healthcare Business, EMD Serono
Philip M. Arlen, President & Chief Executive Officer, Precision Biologics, Inc.
Tim Kievits, Director Healthcare Innovation, VitrOmics Healthcare Holding B.V.
09.30-10.00
Special Address: Updates on Immuno-Oncology Discovery and Development Trends
Rakesh Dixit, Vice President, Research & Development, Global Head, Biologics Safety Assessment, MedImmune
10.00-10.30 Panel Discussion -Harnessing Innovation and Funding in Digital Healthcare and Digital Biology Companies
• Financing and investment considerations
• Discovery and moving to the clinic – challenges and opportunities
• Overcoming hurdles on regulation, reimbursement and pricing
Panellists:
Simon Haworth, CEO, Dynastybio
Michael Heltzen, CEO, BlueSeq Innovations(TBA)
Irina Haivas, Principal, GHO Capital Partners
Keith Woodhouse, Partner, Fieldfisher
10.30-11.00 Morning Refreshment Break
Stream 1: Drug Discovery
and Development -
Immuno-Oncology and
Immuno-Therapy
Stream 2: Proteins,
Antibodies, Regenerative
Medicine Development
Stream 3:
Biomarkers/Precision
Medicine, Diagnostics ,
Liquid Biopsy in Drug
Development
Scheduled Partnering
Meetings x8 and
Exhibition
11.00-11.15 Fred Jacobs, CEO, TYG
Oncology
Birgit Werner, Managing Director,
UGIsense
Will Dracup, CEO,
Biosignatures
11.15-11.30 Michael J. Natan, Ph.D.
Chief Executive Officer
Ultivue Inc.
Cyto-Mine®: a novel single cell
analysis platform for rapid
biopharmaceutical discovery and
cell line development
Frank Craig, CEO, Sphere Fluidics
Milan Bhagat
TriStar Technology Group
LLC (Reserved)
11.30-11.45 Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging
biotech company
presentation
DAY 2 Agenda At A Glance
11.45-12.00
Spinoffs and emerging
biotech company
presentation
Spinoffs and emerging biotech
company presentation
Spinoffs and emerging
biotech company
presentation
12.00-12.30 Panel Discussion – Market Outlook for Immuno-oncology investment
Recent Deal Trends In Immuno-Oncology
• From the Biotech perspective: funding environment, partnerships and exits
• From the Pharma side: deal trends and emerging innovation
• Strategies and tactics for combination therapies
Moderator:
Timothy Herpin, Vice President, Head of Transactions, Business Development, AstraZeneca
Panellists:
John Haurum, CEO, F-star GmbH & F-star Biotechnology Ltd.
Ro Wickramasinghe, Director of Oncology Evaluation, AstraZeneca
Peter Dudek, Principal, Wellington Partners Life Science Venture Capital
Anne Goubier, VP Immunology, Tusk Therapeutics
12.30-13.30 Lunch
Stream 1: Drug Discovery
and Development -
Immuno-Oncology and
Immuno-Therapy
Stream 2: Proteins,
Antibodies, Cell Therapeutic
Development
Stream 3:
Biomarkers/Precision
Medicine, Diagnostics,
Liquid Biopsy in Drug
Development
Scheduled Partnering
Meetings x9 and Start
Up Slam
13.30-14.00 Immuno-oncology
Therapeutic Development
Senior Representative,
Mologen(Reserved)
soloMER™ Biologics;
developing site-specific
therapeutics for
inflammatory disease
Caroline Barelle, CEO,
Elasmogen
Precision Medicine And The
Role of Biomarkers in
Clinical Development
Philip M. Arlen, President &
Chief Executive Officer,
Precision Biologics, Inc.
14.00 – 14.30
ImmTAC® Reagents:
Novel Bi-Functional TCR-
Based Biologics for
Targeted Immunotherapy
Bent Jakobsen, Chief
Scientific Officer, Immunocore
Using High Performance
Capillary Electrophoresis in
the Analytical steps of a
MonoClonal Antibody's life. • Optimising production work
flows by fast accurate analytics.
• Testing stability throughout the
production process and
delivery to point of care.
• Monitoring the efficacy of the
product at the point of care
Stuart Hassard, Chief Scientific
Officer, deltaDOT Ltd
Machine Learning and
Biomarkers
Matthew Hall,
CEO, Co-founder
SimplicityBio SA (Reserved)
14.30 – 15.00 Car T Cells For The
Treatment Of Cancer
GAGbodies: a new class of
biotherapeutics targeting
glycans in immuno-
oncological indications
Andreas Kungl, CEO, Antagonis
Apostle - Enabling the New
Landscape of Liquid Biopsy
• The liquid biopsy
technology - central topic
of precision medicine, a
multi-national strategic
roadmap for the global healthcare.
• The current liquid biopsy
technologies suffer from
suboptimal sensitivity and
specificity.
• Innovative Apostle MiniMax
and Triton technologies,
combining nanotechnology
and artificial intelligence
and improving the
efficiency and accuracy of
liquid biopsy
David Ge, CEO & President,
Apostle Inc
15.00 – 15.30 IO on the Move: New
Targets, New Trends, New
Combinations
Stem Cell Cancer Discovery
and Development
Sandy Primrose, Non-Executive
Chairman, Urosens
Direct, PCR free detection of
microRNAs – A transformation
for RNA biomarker diagnosis
Hugh Ilyine, CEO, DestiNA
Genomics
15.30 – 16.00 Afternoon Refreshments
16.00-16.30 Immuno-oncology
Therapeutic Development
Anne Goubier, VP
Immunology, Tusk
Therapeutics
Therapeutic antibodies to
GPCRsDJS Antibodies’
technology for the discovery of
high quality mAbs to GPCRs
• Case study – oncology
• Future pipeline development
David Llewellyn, CEO, DJS
Antibodies
Diagnostics Development
Heinrich Roder, CTO, Biodesix
16.30 – 17.00 How to value a Biotech Start-up company
What’s important when speaking about valuation (pre-money / post money)
• Overview of valuation approaches
• Valuation of a therapeutic Biotech product (incl. example)
• Conclusion
Patrik Frei, Founder and CEO, Venture Valuation AG
END OF SHOWCASE
BOOKING FORM HOW TO REGISTER:
FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: [email protected]
Please complete fully and clearly. Please photocopy for additional delegates Title: …………………………… Forename: ………………………………………………….. Surname: …………………………………………………... Company/Organisation: …………………………………………………………………………………………………………………………………………. Job Title: …………………………………………………………………………………………………………………………………………………………... Address: ……………………………………………………………………………………………………………………………………………………………. Postcode: …………………………... Country: …………………………... Direct Telephone: ………………………………... Mobile: …………….…………….. Switchboard: ……………………….. Fax: ……………………….. Email: ……………………………………………………………………………………………………………………………………………………………….. Signature: ………………………………………………. Date: ……………………………………………………..
Number of delegates:
CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number:
Valid from: /
Expiry Date: /
Security code:
Cardholders name ………………………………………...
Signature: …………………………………………………. Date: ……………………………………….
PLEASE INVOICE ME:
Invoice Address (if different from above) ……………………………………………………………………… ……………………………………………………………………… ……………………………………………………………………... PO Number (if applicable) ………………………………………. * Please note there is a £50 plus VAT handling charge for payment via invoice * All card payments will be subject to a 3% bank charge or 4% AMEX charge * Payment to be made within 30 days of invoice
Registration Fees
Delegate Details
How to Pay (choose one of the following payment options)
I would like to attend: (Please tick as appropriate) REGISTRATION AND PARTNERING ACCESS (FULL PASS) • Full access to the 1-2-1 networking portal pre-event • Up to 17 Meetings per day (34 meetings over 2 days) • 1x full conference pass
Academic Spinoffs, Biotech spinoffs, TTOs: £950+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,
Solution Providers: £2450+VAT POSTER PRESENTATION • 1x A0 portrait poster display in exhibition hall (must register for full pass)
Academic Spinoffs, Biotech spinoffs, TTOs:
£150+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,
Solution Providers: £250+VAT SPEAKER PRESENTATION • 15 Minute presentation platform in conference room (must register for full pass)
Academic Spinoffs, Biotech spinoffs, TTOs: £250+VAT
VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors, Solution Providers: £1000+VAT EXHIBITION • 2x2m table-top in main Exhibition Hall (must register for full pass)
Academic Spinoffs, Biotech spinoffs, TTOs:
£500+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,
Solution Providers: £1000+VAT
If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected] www.biotechinvestment-showcase.com
Terms & Conditions of Booking
I agree to the terms and conditions (Please refer to page 2 for the terms and conditions)
To obtain information on our full sponsorship opportunities, please contact [email protected]
Sponsorship Opportunities
Terms & Conditions of Booking
1. Definitions In these terms and conditions, the following terms have the following meanings: - “Contract Price” The total cost payable for the Package as shown on the official booking form “Delegate/Sponsor” Any person who has been invited by the Organisers to attend the showcase, start up slam and partnering meetings OR Any company or person who has purchased a package or any agent representative or employee of such company or person “Event” named in the Terms and Conditions Title above "Meeting Area" The meeting area/exhibition space designated for the Sponsor/Exhibitor at the Event “Organisers” Oxford Global Marketing Limited “Package” The accommodation, area for meetings and conference sessions in a hotel venue where the Event will take place in-cluding meals but not beverages unless specified by the Organiser. 2. Law These terms shall be construed in accordance with English law and subject to the exclusive jurisdiction of the English courts. 3. Application for Packages Applications must be made on the Organiser’s official booking form, which must be completed in full. The Organisers may accept applications in writing, by email or facsimile, or accept a deposit payment in lieu of written application at their sole discretion, and on the understanding that these terms and conditions apply to any application and supersede any terms and conditions of the Delegate/Sponsor. Any alterations of these terms and conditions cannot be accepted without the prior written consent of a direc-tor of the Organiser. 4. Payment The Delegate/Sponsor shall pay the contract price in accordance with the dates set out in the official booking form. If any of the above payments shall be 30 days in arrears whether demanded or not, the contract may at any time thereafter be terminated forthwith by the organisers by notice in writing to these parties. Upon termination all instalments paid shall be forfeited and the balance shall become immediately payable. Such termination shall not prejudice any rights or claims by the Organisers against these parties in respect of any prior breach. 5. Contract and Termination On the acceptance of the official booking form by the Organisers, a contract relating to the package purchased by the Delegate/Sponsor will exist between these parties and the Organisers as set out in these terms and conditions. In case of non payment of any sum due from these parties whether legally demanded or not, or of the breach, or non-observance, by these parties of any of these terms and conditions, or any regulations to be observed by these parties, the Organisers shall have the right to terminate the contract and to remove and exclude these parties from the Event without prejudice to the right to recover all sums payable by these parties and all other claims against it, and any loss of damage sustained by the Organisers. 6. Withdrawal or Cancellation In the event of withdrawal or cancellation, the following amounts shall become immediately payable: More than 6 months prior to the event 35% cancellation fee Between 6 and 3 months prior 75% cancellation fee Less than 3 months prior to the event full cancellation fee Any notification of withdrawal or cancellation must be in writing and sent to the Organisers by recorded delivery. Cancellation will be deemed to have occurred when written notification has been received by the Organisers. 7. Occupation of Meeting Area The Delegate/Sponsor (subject to contracted package) must occupy their allocated Meeting Area by the Event opening time on the first day of the Event. Failing to do so will be deemed a cancellation of Package, in which case the terms and conditions relat-ing to withdrawal or cancellation will apply, and the Package may be offered to another Delegate/Sponsor. 8. Bankruptcy In the event of bankruptcy, liquidation, having an administrator or receiver appointed, or entering into a voluntary arrangement with its creditors; the Delegate/Sponsor’s contract may be terminated at the option of the Organisers and the full contract price will be due and payable forthwith. 9. Prohibition of Transfer A Delegate/Sponsor may not assign, sublet or share possession of, or grant licenses in respect of the whole or any part of the Package nor may any cards, advertisements, or printed matter of firms who are not bona fide Delegate/Sponsor’s be exhibited in or distributed from any area. This does not apply to firms which are subsidiaries, agents or principals of the Solution Provider and which are duly listed on the official application form at the time of booking.
If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]
Terms & Conditions of Booking
10. Postponement or Abandonment The Delegate/Sponsor shall not have any claim against the Organisers in respect of any loss or damage consequent upon the failure for whatever reason to hold any part of the Event or if the hotel venue at which the Event is scheduled to take place be-comes wholly or partially unavailable for the holding of the Event. If, by the re-arrangement or postponement of the period of the Event, or by substitution of another hotel venue for the holding of the Event, or any other reasonable action, the Event can take place, the contract shall remain in force. If the Organisers abandon the Event other than by reason of events or circumstances beyond its reasonable control, the Organisers will reimburse the Contract Price. If the Event is abandoned by the Organisers by reason of events or circumstances beyond it’s reasonable control, the Organiser will reschedule the Event (to be held within 12 months of the original event) but no reimbursement will be made by the Organiser and the Delegate/Sponsor will remain liable to pay the Contract Price. 11. Liability Save in the case of death or personal injury caused by the Organisers' negligence, the Organisers are not responsible for the health & safety of any meeting or conference or any property of the attendees or any third party, or for any loss or damage sus-tained by these parties or any third party, in each case for any reason whatsoever. Delegates/Sponsors should have in place their own insurance to cover all such liabilities and risks. 12. Event Promotional Materials Only the signage provided by the Organisers will be used by the Delegate/Sponsor. The Organisers will notify the Delegate/Sponsor of the nature of available meeting facilities and of promotional material e.g. display stands and brochures that they may display. The Organisers reserve the right (without being required to give notice) to alter the layout of any meeting floor plan at any time and to relocate these parties to another area. 13. Information and Copyright Information supplied by the Organisers in relation to any event is accurate to the best of their knowledge and belief, but shall not constitute any warranty or representation by the Organisers and any inaccuracy or mistake in such information or omission from it shall not permit the Delegate/Sponsor to cancel a confirmed booking. All information and data relating to the Event, which is supplied by the Organisers to the Delegate/Sponsor is the copyright of the Organisers and cannot be passed on to any third party for any purpose. The Organiser processes information about each Delegate/Sponsor in accordance with the Organiser's privacy policy, a copy of which is available on our website or by written request. By submitting information to the Organiser, the Delegate/Sponsor con-sents to such processing and warrants that all data provided is accurate 14. Substitution The Delegate/Sponsor may substitute a representative up to 3 weeks before the event provided that this is conveyed via email to the Organiser and also by completing a new on-line application form and stating in the relevant box on the form the name of the person s/he is replacing. The replacement Delegate/Sponsor will take over the partnering meetings agreed by the original party, although these can be cancelled if the meetings are no longer relevant. 15. Photography/ Video Photography For promotional purposes, there may be professional photography and video production taking place during the conference. Del-
egates who do not wish to be filmed or recorded should advise the organisers by email to [email protected], prior to the event.
If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]